Symbols

PROC(Delisted)

Procaps·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

Bullish Abandoned Baby

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PROC

Procaps Group, S.A.

A leading developer and manufacturer of customized softgel capsules for the healthcare and nutraceutical industries

Industry

Established Date

12/06/2018

Listing Date

12/09/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

5,564

Fiscal Year Ends

12-31

Website

www.procapsgroup.com

Security Type

Common stock

Office address

9 rue de Bitbourg, L-1273, Luxembourg, Grand Duchy of Luxembourg, R.C.S. Luxembourg: B253360

Business

Introduction

Procaps Group, S.A. was incorporated on December 6, 2018. The ProCaps Group is a developer of pharmaceutical and nutritional health solutions, pharmaceuticals and hospital supplies in more than 50 countries on five continents. ProCaps has direct operations in 13 countries in Latin America. ProCaps develops, manufactures and sells over-the-counter and prescription drugs, nutritional supplements and high-efficiency clinical solutions.

Company Financials

EPS

PROC has released its 2023 Q3 earnings. EPS was reported at 0.08, versus the expected 0.05, beating expectations. The chart below visualizes how PROC has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

PROC has released its 2023 Q3 earnings report, with revenue of 118.41M, reflecting a YoY change of 7.25%, and net profit of 8.20M, showing a YoY change of -63.69%. The Sankey diagram below clearly presents PROC's revenue sources and cost distribution.